Tvardi Therapeutics, Inc.
TVRD
$22.59
-$2.03-8.23%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Net Income | 84.02% | ||||
| Total Depreciation and Amortization | -- | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | -15.59% | ||||
| Change in Net Operating Assets | 16.50% | ||||
| Cash from Operations | 84.59% | ||||
| Capital Expenditure | -- | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -- | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | 246.86% | ||||
| Cash from Financing | 246.86% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | 28.94% | ||||